Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496873 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00496873: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00496873 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00496873, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The goal of the clinical research study is to learn if treatment with a combination of three drugs, Cytoxan (cyclophosphamide), Rituxan (rituximab) and Nipent (pentostatin), will help to control the disease in patients with previously untreated non-Hodgkin's lymphoma, CLL, or bulky lymphoma. The safety of this treatment will also be studied.
Interventions
- DRUG Cytoxan
- DRUG Rituxan
- DRUG Nipent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00496873
The ClinicalTrials.gov registry entry for NCT00496873 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cytoxan is the first listed.
NCT00496873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00496873 about?
NCT00496873 is a clinical study titled "Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan". The goal of the clinical research study is to learn if treatment with a combination of three drugs, Cytoxan (cyclophosphamide), Rituxan (rituximab) and Nipent (pentostatin), will help to control the disease in patients with previously untreated non-Hodgkin's lymphoma, CLL, or bulky lymphoma. The saf...
What is the current status of trial NCT00496873?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2005-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00496873?
The interventions under investigation include: Cytoxan (DRUG), Rituxan (DRUG), Nipent (DRUG).
Who is sponsoring clinical trial NCT00496873?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.